Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GIANT BIOGENE HOLDING CO., LTD
巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Giant Biogene Holding Co., Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce that Shaanxi Giant Biotechnology Co., Ltd., a wholly-owned subsidiary of the Company, has received the Medical Device Registration Certificate of the People's Republic of China (Registration Certificate No.: Guo Xie Zhu Zhun 20263131219) issued by China National Medical Products Administration in respect of the product titled Cross-linked Recombinant Collagen Implant (the "**Product**") today. The Product adopts the full-length sequence of mature human type III collagen, which consists of 1,068 amino acids in total, fully retaining the natural functional domains of collagen, and employs a physical cross-linking process with no risk of chemical cross-linking agent residues to form a stable three-dimensional mesh gel, which is intended for intradermal injection into the dermis layer of the neck to correct moderate to severe horizontal neck wrinkles.

The Product was granted priority review by the Medical Device evaluation division of China National Medical Products Administration in December 2024. Following this approval, the Product becomes the world's first cross-linked recombinant type III collagen filler for neck wrinkle filling. Following the successful approval of the two previous implant products, the successful approval of this Product will further enrich and optimize the Company's product matrix, making the Company the world's first enterprise that possesses both recombinant type I and type III collagen implant products with indications covering two major areas, namely facial wrinkles and neck wrinkles, reflecting the Company's profound R&D innovation and industrialization capabilities, and continuously expanding incremental market space.

Recently, the Company's Collgene Reborn (可麗金芯生) Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers product has been launched for the first time, marking the Company's official commercialization in the field of high-end biological regeneration materials. The national "15th Five-Year Plan" proposal suggests making forward-looking arrangements for six future industries including biomanufacturing. Looking ahead, the Company will leverage its over 20 years of research accumulation in synthetic biology, continue to advance the market promotion of the approved products and the R&D of pipeline products, and help accelerate the domestic biomanufacturing and regenerative materials industry towards a new stage of standardized, high-end and technology-driven high-quality development.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi'an, the PRC, 17 June 2026

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive Directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive Directors.